Biosynex SA operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Biosynex SA with three other
companies in this sector in France:
Millet Innovation Sa
sales of 21.90 million Euro [US$24.25 million]
Les Trois Chenes
(35.45 million Euro [US$39.25 million]
(14.54 million Euro [US$16.10 million]
of which 100%
was Research & Development).
During the year ended December of 2018, sales at
Biosynex SA were 31.21 million Euro (US$34.56 million).
increase of 2.2%
versus 2017, when the company's sales were 30.54 million Euro.
This was the fifth consecutive year of sales increases at Biosynex SA
(and since 2013, sales have increased a total of 1,613%).
Sales of Services saw an increase
that was more than double the company's growth rate: sales were up
980.2% in 2018, from
26,045.00 Euro to 281,328.00 Euro.
Biosynex SA also saw significant increases in sales in
Sale of Finished Goods (up 17.7% to 13.27 million Euro)
Income From Related Activities (up 25.4% to 276,588.00 Euro)
Sales of Intermediate Products (up 71.5% to 166,384.00 Euro)
Not all segments of Biosynex SA experienced an increase in sales in 2018:
sales of Sale of Goods fell 8.4% to 17.49 million Euro.